INTRODUCTION
Palmitoylation is a posttranslational process in which fatty acids, predominantly the 16-carbon palmitate, are covalently bonded to cysteine residues through a thioester linkage. A wide variety of proteins that play key roles in different cellular functions are palmitoylated (1, 2) . Palmitoylation is also one of a few posttranslational modifications that are reversible, and cycles of palmitoylation and depalmitoylation can occur. The mechanisms by which proteins are palmitoylated and depalmitoylated have not been well characterized, but enzymes can catalyze both events (3) . Palmitoyl transferases have been identified (4-6) as well as two thioesterases that remove palmitate from proteins (7, 8) . Mutant forms of protein palmitoyl thioesterase 1 (8) are associated with forms of lysosomal storage disease or Batten's disease (9, 10) .
While a wide variety of proteins have been found to be palmitoylated, limitations in the techniques used to assay protein palmitoylation have prevented a quantitative analysis of their palmitoylation. Virtually the only method available to detect palmitoylation of a specific protein of interest is by metabolically labeling with radiolabeled palmitate in living cells. The amount of labeling and its detection are dependent on several factors including the ability of labeled palmitate to enter cells, the ratio of labeled and unlabeled palmitate that is achieved in cells, and the amount of palmitoylation that had occurred prior to the labeling period. As a consequence, metabolic labeling with radiolabeled palmitate cannot provide quantitative information regarding the extent of acylation and may not detect palmitoylation in proteins that have relatively low levels of expression. Recently, a quantitative in vitro assay for palmitoyl acyl transferase activity has been developed using a fluorescently labeled substrate peptide (11) . Palmitoylated proteins can also be identified and analyzed by mass spectrophotometry (12) (13) (14) (15) . However, techniques using mass spectrophotometry require a significant amount of purified protein, as well as special equipment and expertise not available in most laboratories.
Palmitoylated proteins fall into two basic categories: (i) membrane-associated proteins of cytosolic origin, and (ii) integral membrane proteins. Relatively few integral membrane proteins have been shown to be palmitoylated. One reason is that integral membrane proteins, such as ion channels and receptors, are expressed at relatively low levels making detection of their palmitoylation difficult. Receptors and ion channels found to be palmitoylated, such as Na + channels (16) , Ca 2+ channels (17, 18) , serotonin (5HT) receptors (19, 20) , and kainate-type glutamate receptors (21) , were assayed in cell lines that expressed these proteins at high levels. In our attempts to examine whether neuronal nicotinic acetylcholine receptors are palmitoylated, we found that our ability to assay palmitoylation by metabolically labeling with radiolabeled palmitate was limited. In this study, we describe new, more sensitive methods for detecting protein palmitoylation. These methods are based on the susceptibility of the fatty acylthioester bond to neutral hydroxylamine cleavage, resulting in removal of the fatty acid and generation of a free sulfhydryl. Subsequently, sulfhydryl-specific reagents, such as 3 
MATERIALS AND METHODS

Subunit Constructs, Cell Lines, and Transfection
Hemagglutinin (HA) epitope-tagged chimeric cDNA composed of the Nterminal half of the chick α7 subunit and the C-terminal half of the mouse 5HT 3A subunit (α7/5HT 3A ) in a pMT3 expression vector (22) was prepared as previously described (23) . Myc-tagged synaptosomal protein of 25 kDa (SNAP-25) was a kind gift from Dr. Maurine Linder, Washington University. Myctagged postsynaptic density protein of 95 kDa (PSD-95) was from Dr. John Marshall, Brown University, and the palmitoylation-deficient mutant PSD-95 construct, in which cysteines 3 and 5 are mutated to serines, was from Dr. David Bredt (University of California, San Francisco). The human kidney epithelial cell line, tsA201, was a gift from Dr. J. Kyle (University of Chicago) and was maintained in Dulbecco's modified Eagle's medium (DMEM; GibcoBRL, Grand Island, NY, USA) supplemented with 10% calf serum (CS; Hyclone, Logan, UT, USA). Cells were transiently transfected using a calcium phosphate protocol (24) . Unless otherwise indicated, all reagents and supplies were from Sigma (St. Louis, MO, USA).
Metabolic Labeling
Cell cultures were incubated in methionine-free DMEM for 10-15 min and labeled in methionine-free DMEM containing 100 µCi/mL of 35 
Solubilization and Affinity Purification
Rat brain homogenates were prepared as previously described (25, 26) . Brain tissue or cultured cells were solubilized in lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, pH 7.4, 0.02% NaN 3 ) containing 1%-2% Triton ® X-100, 2 mM phenylmethylsulfonyl fluoride, 10 µg/mL each of chymostatin, pepstatin, leupeptin, tosyl-lysine chloromethylketone, and 10-50 mM N-ethylmaleimide (NEM) as indicated. Lysates from brain or cultured cells were clarified by centrifugation at 10,000× g for 30 min at 4°C, and the supernatants were incubated with Sepharose ® 4B (Amersham Biosciences) to remove proteins that bound nonspecifically to the Sepharose. All samples were centrifuged, and the supernatants were rotated overnight with either saturating amounts of α-bungarotoxin (Bgt; Biotoxins, St. Cloud, FL, USA) conjugated to Sepharose 4B (Bgt-Sepharose), monoclonal antibody (MAb) 12CA5 (anti-HA antibody), anti-myc MAb, anti-SNAP-25, or anti-PSD-95 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The protein-antibody complex was precipitated with Protein G-Sepharose (Amersham Biosciences).
NEM [ethyl-1,2-3 H] ( 3 H-NEM) (1 mCi/mL; PerkinElmer Life and Analytical Sciences) supplied in pentane was diluted with absolute ethanol to a final concentration of 5 µM (0.25 mCi/mL) in a methanol-dry ice bath. Immunoaffinity purified protein bound to Protein G-Sepharose was treated with 1 M hydroxylamine, pH 7.4, for 1 h at room temperature. Controls were incubated in the presence of 1 M Tris, pH 7.4. The beads were washed twice with lysis buffer plus 1% Triton X-100. The beads were resuspended in 8 volumes of lysis buffer containing 0.5 µM 3 H-NEM and rotated at room temperature for 3 h. Samples were run on SDS-PAGE and transferred to nitrocellulose membranes. Immunoblots were performed with the indicated antibodies and an enhanced chemiluminescenc kit (ECL™; Amersham Biosciences). After blotting, membranes were stripped, dried, and exposed to a 3 H-specific phosphor screen (Amersham Biosciences) for 24 h (see Figures 1A and 3A ), 48 h (see Figure 3C ), 3 days (see Figure 4A ), or 5 days (see Figure 4C ). Screens were scanned on a PhosphorImager ® (Amersham Biosciences), and quantitation of scans was performed on ImageQuant ® software (Amersham Biosciences). Attempts to use commercial 3 H-NEM concentrations higher than 0.5 µM resulted in excessively high levels of solvent in the samples (approximately 20% at 1 µM 3 H-NEM), which could result in protein denaturation or interfere with binding of the protein to the Sepharose beads. Therefore, for saturation labeling experiments, the commercial label was diluted 1:150 with unlabeled NEM in lysis buffer. Purified α7/5HT 3A subunits were labeled with varying concentrations of the diluted NEM after hydroxylamine treatment. The amount of NEM incorporated into each sample was determined by scintillation counting.
To label palmitoylation sites with the sulfhydryl-specific biotinylating reagent, Btn-BMCC, α7/5HT 3A receptors were precipitated with Bgt-Sepharose affinity resin and treated with or without 1 M hydroxylamine. The receptor protein was labeled with Btn-BMCC (1 µM) for 2 h at room temperature. The labeled proteins were run on SDS-PAGE and transferred to nitrocellulose membranes. Blots were probed with streptavidin-conjugated horseradish peroxidase (HRP), and the labeled proteins were detected with ECL. For biotinylation experiments designed to measure 125 I-Bgt (PerkinElmer Life and Analytical Sciences) binding sites, intact cells were resuspended in 5 mM Tris containing protease inhibitors and taken through two cycles of freeze-thaw. Membrane fractions were collected by centrifugation at 15,000× g for 30 min and resuspended in phosphate-buffered saline (PBS) containing 20 mM NEM. After removal of excess NEM, samples were incubated in 1 M hydroxylamine as previously described and subsequently labeled with Btn-BMCC at room temperature for 2 h. Samples were solubilized in lysis buffer, and the lysates were incubated with 125 I-Bgt and streptavidin-agarose. In order to assess total binding, samples labeled in parallel were precipitated with concanavalin A-agarose, which brings down greater than 96% of the Bgt-binding sites.
RESULTS
Palmitoylation of α-Bungarotoxin
Binding Nicotinic Receptor Subunits
Our laboratory has been characterizing the posttranslational processing of the neuronal nicotinic receptors that are the Bgt binding sites in brain. Native Bgt-binding receptors (BgtRs) are composed solely of α7 subunits (25, 26) , and α7 subunits fully mature into functional receptors only if expressed in cells of neuronal origin (27, 28) . Because muscle nicotinic receptor subunits are palmitoylated, and palmitoylation may be critical for their expression (29) , we wanted to test whether neuronal BgtRs are palmitoylated. Using a PC12 cell variant that expresses relatively large numbers of BgtRs (28), attempts to metabolically label BgtRs with 3 H-palmitate were inconclusive (data not shown). For this reason, we were uncertain whether the level of BgtR expression was sufficient to detect palmitoylation by labeling with 3 H-palmitate. As an alternative, we tested whether BgtRs assembled from α7/5HT 3A subunits (30) are palmitoylated. Unlike α7 subunits, the chimeric α7/5HT 3A subunits form high levels of functional BgtRs when heterologously expressed and appear to be processed in the same way as native α7 subunit receptors (23, 25) . We metabolically labeled cells of the human embryonic kidney tsA201 cell line (tsA201 cells) transiently expressing hemagglutinin epitope (HA)-tagged α7/5HT 3A subunits with 3 H-palmitate at a specific activity of 1 mC/mL. These conditions resulted in the incorporation of 3 H-palmitate into α7/5HT 3A subunits ( Figure 1A , lane 1). Hydroxylamine treatment of parallel samples resulted in complete removal of 3 H-palmitate from labeled subunits ( Figure 1A , lane 2), which is consistent with the palmitoylation of cysteine residues on the α7/5HT 3A subunits.
H-NEM Labeling of Palmitoylation Sites
The level of 3 H-palmitate labeling of α7/5HT 3A receptors, which are expressed at levels 30-50 times higher in tsA201 cells than α7 receptors in PC12 cells (25) , implied that 3 H-palmitate labeling was not sensitive enough to assay palmitoylation of the native α7 subunits in PC12 cells. The ability of hydroxylamine treatment to remove the attached palmitate ( Figure 1A , lanes 1 and 2) suggested a different method to assay for the palmitoylation of BgtRs. Hydroxylamine treatment hydrolyzes the thioester bond resulting in a free sulfhydryl group at the site at which the cysteine residue was palmitoylated. The concentration of hydroxylamine used in our protocol (1.0 M) appears to be sufficient to hydrolyze any cysteine-palmitate thioester bond, even for proteins that are relatively resistant to hydroxylamine cleavage (31) . Subsequently, the site that was previously palmitoylated can be labeled using reagents that cross-link with free sulfhydryl groups. This idea was tested on α7/5HT 3A receptors in parallel with the 3 H-palmitate labeling. Cells were solubilized in 10-50 mM NEM to block any free sulfhydryls present prior to the hydroxylamine treatment. α7/5HT 3A subunits were then immunoprecipitated using anti-HA antibodies. The purified subunits were treated with hydroxylamine followed by incubation for 3 h in 0.5 µM 3 H-NEM at a specific activity of 25 µC/mL. The tritium signal in these subunits ( Figure 1A, lane 3) was significantly stronger than an equivalent number of 3 H-palmitate-labeled subunits ( Figure 1A, lane 1) by a factor of six ( Figure 1B) , even though the specific activity of the 3 H-NEM was 40 times less than that of the 3 H-palmitate. The blot in Figure 1A (lanes 3 and 4) was overexposed to reveal that a small amount of nonspecific 3 H-NEM labeling was occasionally observed when the receptors were not treated with hydroxylamine. This labeling in the absence of hydroxylamine was probably due to rare incomplete alkylation of all of the free sulfhydryls during solubilization ( Figure 1A, lane 4) .
We examined the migration on SDS-PAGE of both hydroxylamine-treated and untreated α7/5HT 3A subunits that had been metabolically labeled with 35 S-methionine. Hydroxylamine did not significantly alter either the migration or amount of the α7/5HT 3A subunits (Figure 1A, lanes 5 and 6) . Furthermore, as shown in Figure 2B , α7/5HT 3A BgtRs treated with hydroxylamine still retain the ability to bind ligand. Thus, under these conditions, hydroxylamine treatment appears to have little effect on the subunits other than the removal of the attached palmitate.
The commercially available 3 H-NEM stock solution limited the 
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concentration of NEM that could be used for labeling to 0.5-1 µM. This concentration of NEM is not sufficient to label all of the palmitoylation sites on the protein. To determine the NEM concentration at which all of the sites are labeled, the commercial stock of 3 H-NEM was diluted with unlabeled NEM. Purified α7/5HT 3A subunits were then treated with hydroxylamine and labeled in various concentrations of the diluted NEM as indicated ( Figure 1C ). The amount of NEM incorporated was determined by scintillation counting. In parallel samples, the amount of 125 I-Bgt bound was determined and used as a measure of receptor expression. As shown in the Figure 1C , saturation of α7/5HT 3A palmitoylation sites was achieved between 30 and 100 µM NEM, corresponding to 1.35 pmol NEM/pmol Bgt bound. This stoichiometry of palmitoylation is roughly equivalent to 1 palmitate/ subunit, since 4 to 5 Bgts bind per α7/5HT 3A receptor (28) and there are 5 subunits/receptor (25) . At 0.5 µM NEM, which is the concentration used in experiments in Figure 1 , A and B, approximately 0.10 pmol NEM are incorporated per pmol Bgt bound ( Figure  1C) . Thus, the amount of NEM that can be incorporated into α7/5HT 3A BgtRs is 13.5-fold greater than in Figure 1 , A and B. This indicates that the 3 H-NEM signal of α7/5HT 3A subunits could be much greater if a higher concentration of 3 H-NEM with the same or greater specific activity were used for labeling.
Biotinylation of Palmitoylation Sites
Free sulfhydryl groups generated by hydroxylamine removal of palmitate can also be labeled with nonradioactive sulfhydryl-specific reagents that are biotinylated, fluorescently labeled, or labeled with chemiluminescent probes. This variation of our technique was again tested using α7/5HT 3A chimeric subunits. The purified subunits were treated as before with NEM and then hydroxylamine to cleave the thioester bond. The sulfhydryl-specific reagent, Btn-BMCC, was used in place of 3 H-NEM. The labeling of the palmitoylation sites with Btn-BMCC was assayed using strepavidin-HRP ( Figure  2A, lane 2) . No labeling with Btn-BMCC was observed for samples with an equivalent amount of protein (Figure 2A , compare immunoblot samples in lanes 3 and 4), but not treated with hydroxylamine ( Figure 2A, lane 1) .
As another example of the potential use of the biotinylating reagent Btn-BMCC, membrane preparations from cells expressing α7/5HT 3A BgtRs were prepared and treated with NEM to block free sulfhydryls. Samples were subsequently treated with hydroxylamine and labeled with Btn-BMCC for 2 h at the concentrations shown in Figure 2B . The membranes were solubilized, and the labeled proteins were precipitated with streptavidin-agarose. The percentage of total 125 I-Bgt sites precipitated with streptavidin-agarose after biotinylation with Btn-BMCC was measured by comparing 125 I-Bgt binding of streptavidin-agarose precipitated samples to 125 I-Bgt binding precipitated with concanavalin A-Sepharose, which precipitates virtually all solubilized BgtRs. At a saturating concentration of 100 µM Btn-BMCC, streptavidin-agarose precipitated 37% of the total receptor pool ( Figure 2B ). The Btn-BMCC labeling at palmitoylation sites again is highly specific since streptavidinagarose precipitated no BgtRs beyond background from membranes treated with Btn-BMCC but not with hydroxylamine ( Figure 2B ).
Assaying the Palmitoylation of SNAP-25
To further test our new protein palmitoylation methods, we assayed the palmitoylation of SNAP-25. The palmitoylation of this protein has previously been characterized by metabolic labeling with 3 H-palmitate (32, 33) , and we wanted to compare labeling of palmitoylation sites with 3 H-NEM to labeling with 3 H-palmitate in proteins already known to be palmitoylated. A myc epitope-tagged construct of SNAP-25 ( Figure 3A ) was transiently expressed and 3 H-palmitate-or 3 H-NEM-labeled in parallel sets of cultures. The myc epitope allowed precipitation from cell lysates with anti-myc antibodies. SNAP-25 was immunoprecipitated from unlabeled cells, treated with hydroxylamine, and labeled with 3 H-NEM at a concentration of 0.5 µM. 3 H-NEM labeling of SNAP-25 (Figure 3A, lane 2) only occurred for the hydroxylamine-treated samples (Figure 3A, compare lanes 1 and 2) even though the levels of expression of the hydroxylamine-treated and untreated samples were equivalent ( Figure 3A , compare lanes 5 and 6). SNAP-25 was labeled with 3 H-palmitate ( Figure 3A , lane 3) via a hydroxylamine-sensitive linkage ( Figure 3A, lane 4) . As previ- ously reported (34) , palmitoylation results in decreased mobility of SNAP-25 on SDS gels ( Figure 3A, compare  lanes 2 and 3) . The 3 H-NEM labeling was 12-fold greater than the 3 H-palmitate labeling for SNAP-25 ( Figure  3B ) as determined by PhosphorImager analysis of gel bands from three separate determinations. The differences in 3 H-palmitate and 3 H-NEM labeling were obtained at an NEM concentration of 0.5 µM. This concentration of NEM was not sufficient to saturate all of the available palmitoylation sites as shown for α7/5HT 3A subunits ( Figure  1C ), and much better 3 H-NEM labeling could be obtained with a higher concentrations of NEM with this or a greater specific activity.
Another advantage of our new methods is that protein palmitoylation can be assayed after purification of the protein. SNAP-25 was used to test whether we could assay palmitoylation of a protein purified from a rat brain preparation. Rat brain homogenates were solubilized in 50 mM NEM to block free sulfhydryls. SNAP-25 was purified from brain lysates with anti-SNAP-25-conjugated agarose followed by treatment with hydroxylamine and labeled with 3 H-NEM. As shown in Figure 3 , 3 H-NEM labeling specifically detected brain SNAP-25 palmitoylation ( Figure 3C, lane 2) , since no labeling was observed in samples that were not treated with hydroxylamine ( Figure 3C, lane 1) . Immunoblot analysis of Figure 3C , lanes 1 and 2, shows that equal amounts of SNAP-25 were loaded onto the gels ( Figure 3C, lanes  3 and 4) .
Assaying the Palmitoylation of PSD-95
As a further test of the fidelity of our new methods to detect protein palmitoylation, we wanted to see whether proteins with their palmitoylation site cysteines mutated could be labeled with 3 H-NEM. Unfortunately, it is not known which cysteines are palmitoylated on α7/5HT 3A chimeric subunits, and it has not been shown definitively which cysteines on SNAP-25 1 and 2, respectively) . The membrane was probed with anti-SNAP-25 monoclonal antibodies (MAbs) (lanes 3 and 4) .
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are palmitoylated (35, 36) . To perform this test we chose a different protein, PSD-95. The palmitoylation of PSD-95 has previously been characterized by metabolic labeling with 3 H-palmitate, and the two N-terminal cysteines on PSD-95 are thought to be the palmitoylation sites, because their removal totally blocks PSD-95 palmitoylation (32, 33) . A myc epitope-tagged construct of wild-type PSD-95 was transiently expressed and 3 H-palmitate-or 3 H-NEM-labeled in parallel sets of cultures ( Figure 4A ). PSD-95 was labeled with 3 H-palmitate ( Figure 4A Figure  4A ). The 3 H-NEM labeling was 5-fold greater than the 3 H-palmitate labeling for PSD-95 ( Figure 4B ) as determined by PhosphorImager analysis of gel bands from three separate determinations. The differences in 3 H-palmitate and 3 H-NEM labeling were obtained at a NEM concentration of 0.5 µM, which was not sufficient to saturate all of the available palmitoylation sites as shown for α7/5HT 3A subunits ( Figure 1C) .
In Figure 4C , we assayed the palmitoylation of a mutated PSD-95, in which cysteines 3 and 5 are changed to serines (32, 33) . No 3 H-NEM (lane 2) or 3 H-palmitate labeling (lane 4) of palmitoylation sites was observed for the mutated PSD-95, while both methods were able to label the wildtype PSD-95 samples (lanes 1 and 3) at equivalent levels of expression (lanes 5 and 6) (see Figure 4C ).
DISCUSSION
Recently, interest in the reversible, posttranslational process of palmitoylation has increased with the realization of its potential role in regulating the function and subcellular localization of proteins. A growing number of proteins are being identified as substrates for palmitoylation. Furthermore, the characterization of the palmitoylation of a number of proteins indicates that palmitoylation regulates a variety of cellular events such as exocytosis, heterotrimeric G-protein signaling, and the trafficking of receptors. Nonetheless, the study of protein palmitoylation is still in its infancy. One reason for this is that so little is known about the enzymes that mediate either palmitoylation or its removal in cells. The identification and characterization of large families of different kinases and phosphatases has been instrumental in our understanding of phosphorylation, which is another reversible, posttranslational process. Two different palmitoyl transferases in yeast have recently been identified (4, 6) . Both have mammalian homologs, suggesting that multiple families of palmitoyl transferases exist. Another reason for a lack of progress has been the limitations of the techniques used to assay protein palmitoylation. Metabolic labeling of proteins with radiolabeled palmitate is inherently inefficient and has been limited to proteins that are abundantly expressed. Even for proteins with high levels of expression, palmitoylation cannot be assayed if only a fraction of the protein is palmitoylated or if its palmitoylation is relatively short-lived. 3 and 4) . Immunoblot analysis with anti-PSD-95 antibodies indicate that comparable levels of wild-type and mutant protein were loaded onto the gels (lanes 5 and 6).
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We have developed new methods of measuring palmitoylation that are quantitative and, consequently, more sensitive than metabolically labeling cellular proteins with radiolabeled palmitate. As we have demonstrated, palmitoylation sites on α7/5HT 3A receptors, PSD-95, and SNAP-25 can be specifically labeled with 3 H-NEM. While the process of palmitoylation primarily attaches palmitate, other fatty acids such as stearate and oleate can substitute for palmitate (5) . The techniques described in this paper cannot distinguish between the covalent attachment of palmitate, stearate, or oleate to cysteine residues via a thioester linkage. However, other lipid modifications, such as prenylation and myristoylation, are not attached by thioester bond formation, and hydroxylamine treatment does not cleave these groups. Thus, our techniques are able to discriminate between palmitoylation, prenylation, and myristoylation.
The methods described in this paper were estimated to be 6 times more sensitive than 3 H-palmitate labeling of α7/5HT 3A receptors ( Figure 1B) , 12 times more sensitive than 3 H-palmitate labeling of SNAP-25 ( Figure 3B ), and 5 times more sensitive than 3 H-palmitate labeling of PSD-95 ( Figure 4B ). These differences in the increase in sensitivity for detecting palmitoylation varied from protein to protein because the amount of 3 H-palmitate labeling is dependent on the amount of palmitoylation that had occurred immediately preceding the labeling period and on the dynamics between palmitoylation and depalmitoylation for each protein. As shown in Figure 1C , the amount of 3 H-NEM labeling is dependent on NEM concentration. The 3 H-NEM labeling of α7/ 5HT 3A receptors, SNAP-25, and PSD-95 was performed at NEM concentrations of 0.5 µM, which did not allow for saturation labeling of the palmitoylation sites. The sensitivity could be increased by more than an order of magnitude with higher 3 H-NEM concentrations at the same specific activity.
Another innovative feature of these new techniques is that they can be used to assay the palmitoylation of proteins expressed in vivo and purified. Such proteins cannot be metabolically labeled with isotopic palmitate. In this paper, we show that the palmitoylation sites of SNAP-25 purified from brain can be labeled with 3 H-NEM ( Figure 3C ). With the exception of one recent study that used mass spectrometry to analyze the palmitoylation of brain myelin proteolipids (14) , this is the first time that a protein expressed in vivo in brain has been demonstrated to be palmitoylated.
The techniques described in this paper are uniquely versatile compared to other methods for assaying posttranslational modifications. The generation of a free sulfhydryl group after removal of palmitate allows the site to be specifically labeled with a variety of sulfhydryl-specific reagents. As demonstrated in Figure 2 , the nonradioactive probe, Btn-BMCC, can substitute for 3 H-NEM to label palmitoylation sites on α7/5HT 3A receptors. We were able to immunoprecipitate the α7/5HT 3A receptors and detect the subunit bands with HRP-conjugated streptavidin and a chemiluminescent assay on Western blot analyses (Figure 2A) . Alternatively, the biotinylation of palmitoylation sites allowed the labeled receptors to be precipitated with streptavidin-agarose and 125 I-Bgt binding to be performed on the palmitoylated fraction of α7/ 5HT 3A receptors ( Figure 2B ). Other nonradioactive sulfhydryl-specific probes should substitute for 3 H-NEM just as well as Btn-BMCC. In particular, fluorescent or chemiluminescentlabeled probes could also be used in assays to measure palmitoylation, each offering different advantages.
